92 Results for "

C-Raf

" in MedChemExpress (MCE) Product Catalog:
Products (92)

92 Results for "C-Raf" in MCE Product Catalog:

  • Isoforms Recommended:
104
104 Publications Verification
Cat. No.: HY-12057
CAS No.: 918504-65-1
Purity:  99.85%
Synonyms: PLX4032; RG7204; RO5185426
Target:  

Raf Autophagy

Research Areas:  

Cancer

Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAF V600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .
loading...
    loading...
83
83 Cited Publications
Cat. No.: HY-14660
CAS No.: 1195765-45-7
Purity:  99.94%
Synonyms: GSK2118436A; GSK2118436
Target:  

Raf CDK

Research Areas:  

Cancer

Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC50s of 5 nM and 0.6 nM for C-Raf and B-Raf V600E, respectively .
loading...
    loading...
83
83 Cited Publications
Cat. No.: HY-14660A
CAS No.: 1195768-06-9
Purity:  99.95%
Synonyms: GSK2118436 Mesylate; GSK 2118436B
Target:  

Raf

Research Areas:  

Cancer

Dabrafenib Mesylate is a potent and selective Raf kinase inhibitor with IC50s of 0.6 and 5.0 nM for Raf V600E and c-Raf, respectively.
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-156498
CAS No.: 2765082-12-8
Purity:  99.48%
Research Areas:  

Cancer

RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (Kd = 195 nM) and KRAS (G12V) (Kd = 292 μM). It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of ERK, CRAF, and RSK, as well as increasing PARP cleavage. This leads to tumor regression, reduces resistance in KRAS G12C cancer models, and demonstrates good tolerability across various RAS cancer models .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-51424
CAS No.: 918505-84-7
Target:  

Raf

Research Areas:  

Cancer

PLX-4720 is a potent and selective inhibitor of B-Raf V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-Raf V600E than wild-type B-Raf.
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-12558
CAS No.: 1454682-72-4
Purity:  98.66%
Synonyms: DP-4978
Target:  

Raf Autophagy

Research Areas:  

Cancer

LY3009120 (DP-4978) is a pan RAF inhibitor which inhibits BRAF V600E, BRAF WT and CRAF WT with IC50s of 5.8, 9.1 and 15 nM, respectively.
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-11004
CAS No.: 878739-06-1
Purity:  99.44%
Target:  

Raf Apoptosis

Research Areas:  

Cancer

AZ 628 is a pan-Raf kinase inhibitor with IC50s of 105, 34 and 29 nM for B-Raf, B-RafV600E, and c-Raf-1, respectively.
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-10966
CAS No.: 405554-55-4
Purity:  99.77%
Target:  

Raf Apoptosis

SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-11010
CAS No.: 345987-15-7
Purity:  98.19%
Target:  

JNK

AS601245 is an orally active, selective, ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC50s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively. AS601245 exhibits 10- to 20-fold selectivity over c-src, CDK2, and c-Raf and more than 50- to 100-fold selectivity over a range of Ser/Thr- and Tyr-protein kinases. Neuroprotective properties .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-10966R
CAS No.: 405554-55-4
Research Areas:  

Cancer

SB-590885 (Standard) is the analytical standard of SB-590885 (HY-10966). This product is intended for research and analytical applications. SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-100510
CAS No.: 1628838-42-5
Purity:  99.92%
Target:  

Raf

Research Areas:  

Cancer

RAF709 is a potent, selective, and efficacious RAF inhibitor with IC50s of 0.4 nM and 0.5 nM for BRAF and CRAF, respectively . Antitumor efficacy .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-18652
CAS No.: 946128-88-7
Synonyms: Ro 5126766; CH5126766
Target:  

MEK Raf

Research Areas:  

Cancer

Avutometinib (Ro 5126766) is a first-in-class dual MEK/RAF inhibitor that allosterically inhibits BRAF V600E, CRAF, MEK, and BRAF (IC50: 8.2, 56, 160 nM, and 190 nM, respectively).
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-112089
CAS No.: 1800398-38-2
Purity:  99.90%
Synonyms: LXH254
Target:  

Raf p38 MAPK Bcr-Abl

Research Areas:  

Cancer

Naporafenib (LXH254) is a potent, selective, orally active, type II BRAF and CRAF inhibitor, with IC50 values of 0.072 and 0.21 nM against CRAF and BRAF, respectively .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-109080
CAS No.: 1446113-23-0
Purity:  99.71%
Synonyms: HM95573; GDC-5573; RG6185
Target:  

Raf

Research Areas:  

Cancer

Belvarafenib (HM95573) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAF v600E and C-RAF respectively .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-10542
CAS No.: 220904-83-6
Purity:  99.49%
Target:  

Raf Apoptosis

Research Areas:  

Cancer

GW 5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, and has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-15767
CAS No.: 1228591-30-7
Purity:  98.93%
Target:  

Raf Aurora Kinase

Research Areas:  

Cancer

TAK-632 is a potent pan-RAF inhibitor with IC50 of 1.4, 2.4 and 8.3 nM for CRAF, BRAF V600E, BRAF WT, respectively.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-10204
CAS No.: 728033-96-3
Purity:  98.57%
Target:  

c-Kit VEGFR c-Fms Apoptosis

Research Areas:  

Cancer

OSI-930 is an orally selective inhibitor of Kit, KDR and CSF-1R (c-Fms) with IC50s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits Flt-1, c-Raf, Lck and low activity against PDGFRα/β, Flt-3 and Abl. OSI-930 has antitumor activity .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-15716
CAS No.: 436133-68-5
Purity:  99.93%
Target:  

Ras Apoptosis

Research Areas:  

Cancer

Kobe0065 is a novel and effective inhibitor of Ras-Raf interaction, competitively inhibiting the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46±13 μM.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-14177
CAS No.: 1093100-40-3
Purity:  98.03%
Target:  

Raf

Research Areas:  

Cancer

Raf inhibitor 1 is a potent Raf kinase inhibitor with Kis of 1 nM, 1 nM, and 0.3 nM for B-Raf WT, B-Raf V600E, and C-Raf, respectively.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-122862
CAS No.: 2351843-48-4
Purity:  99.57%
Target:  

Ras

Research Areas:  

Cancer

RAS inhibitor Abd-7, a potent RAS-binding compound (Kd=51 nM), is a RAS-effector protein-protein interaction (PPI) inhibitor. RAS inhibitor Abd-7 interacts with RAS inside the cells, prevents RAS-effector interactions and inhibits endogenous RAS-dependent signaling. RAS inhibitor Abd-7 impairs the PPI of various mutant KRAS proteins with PI3K, CRAF and RALGDS as well as NRAS Q61H and HRAS G12V .
loading...
    loading...